Revvity Acquires Molecular Design Software Maker ACD/Labs for $72 Million

Introduction

Revvity has completed the acquisition of Advanced Chemistry Development, Inc. (ACD/Labs), a Toronto-based provider of scientific software for analytical characterization and molecular design. The acquisition strengthens Revvity’s software and research informatics portfolio and expands the capabilities of its Revvity Signals platform.

Revvity agreed to acquire ACD/Labs in November 2025, with the transaction subsequently completed in January 2026. According to Revvity’s financial filings, the company paid $72 million in cash at closing, with up to an additional $8 million in contingent consideration tied to revenue-related milestones through 2028.

Revvity Expands Its Scientific Software Portfolio

ACD/Labs develops software designed to support scientific research and development, particularly in pharmaceutical and materials science applications. Its technologies help researchers analyze complex scientific data, characterize molecules, predict molecular properties, and support chemical and manufacturing workflows.

The acquisition gives Revvity access to ACD/Labs’ established portfolio, including the Spectrus platform for analytical and spectral data, Percepta for molecular property and ADMET prediction, Katalyst D2D for experimentation and pharmaceutical development, Luminata for pharmaceutical chemistry and manufacturing decision support, and ADMS for enterprise analytical data management.

Strengthening Revvity Signals

A major objective of the acquisition is to expand the capabilities of Revvity Signals, Revvity’s scientific software business.

By combining ACD/Labs’ analytical and molecular-design technologies with Revvity Signals, the companies aim to create a more connected digital environment for scientific research. The combined platform is intended to help organizations move more efficiently from discovery and development through scale-up and manufacturing.

This integration is particularly relevant as pharmaceutical and chemical companies increasingly digitize research workflows and seek better ways to connect experimental data, analytical information, molecular insights, and manufacturing decisions.

Why ACD/Labs Is Strategically Important

ACD/Labs has more than three decades of experience developing scientific software. The company serves customers across pharmaceutical, chemical, food and beverage, environmental, agrochemical, flavors and fragrances, government, and educational sectors, with a team of more than 200 employees.

Its software capabilities complement Revvity’s broader focus on health science technologies and informatics. Rather than operating as a standalone software acquisition, ACD/Labs can add specialized chemical and analytical intelligence to Revvity’s existing digital ecosystem.

This could help Revvity address a wider range of research and development requirements and provide customers with more integrated software solutions.

Financial Details of the Acquisition

Revvity’s regulatory filing provides additional details about the transaction. The company reported $72 million in cash paid at closing, along with the potential for up to $8 million in contingent cash consideration based on the achievement of specific revenue metrics through 2028.

The acquisition was recorded within Revvity’s Life Sciences segment. Revvity also recognized approximately $32 million in goodwill associated with the transaction.

The financial structure indicates that Revvity has made a relatively targeted investment to strengthen its software and informatics capabilities while linking part of the additional consideration to ACD/Labs’ future performance.

Impact on Pharmaceutical and Chemical R&D

The acquisition comes as pharmaceutical and chemical companies increasingly rely on digital tools to manage growing volumes of scientific and analytical data.

Modern R&D environments generate information from numerous analytical techniques, experiments, instruments, and computational models. Integrating these sources can help scientists make faster and more informed decisions.

ACD/Labs’ technologies are designed around these requirements. Its platforms can support areas such as spectral analysis, molecular property prediction, analytical data management, process development, and chemical decision-making. Combining these capabilities with Revvity Signals could therefore help create a more connected workflow for scientists.

A Broader Move Toward Integrated Scientific Workflows

The acquisition reflects a broader trend in the life sciences and chemical industries: the movement from individual software applications toward integrated digital research environments.

Scientists increasingly need systems that can connect experimental information with analytical results and molecular insights rather than managing each stage through separate tools. Revvity has positioned the ACD/Labs acquisition as a way to strengthen this connection between analytical data and actionable scientific insights.

For pharmaceutical and materials companies, such integration could support improved data accessibility, collaboration, decision-making, and process development.

What Happens to ACD/Labs?

Following completion of the acquisition, ACD/Labs became part of Revvity Signals Software. ACD/Labs states that the acquisition was completed in January 2026 and that the combined organization will continue supporting scientific workflows from discovery and development through scale-up and manufacturing.

The integration is also already affecting the company’s software operations. For example, ACD/Labs’ technical support has transitioned to Revvity Signals, while some products are being managed as part of the broader Revvity software ecosystem.

Conclusion

Revvity’s acquisition of ACD/Labs for $72 million in upfront cash, plus up to $8 million in contingent consideration, represents a strategic investment in scientific software and research informatics.

By bringing ACD/Labs’ molecular design, analytical characterization, and chemical intelligence capabilities into Revvity Signals, the company aims to strengthen its ability to provide connected digital workflows across pharmaceutical and materials science research.

As laboratories and R&D organizations continue to generate increasingly complex scientific datasets, the integration of analytical software, molecular intelligence, and research informatics could become increasingly important. The ACD/Labs acquisition positions Revvity to participate more deeply in this evolving market while expanding the capabilities available to its pharmaceutical, biotechnology, chemical, and research customers.